Generic NeoMercazole

Order cheap Generic NeoMercazole () without dr prescription in the United States

In our USA pharmacy, you can buy NeoMercazole without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
NeoMercazole (carbimazole) is an antithyroid medication used to treat hyperthyroidism, including Graves' disease and toxic goiter. It is a prodrug that is rapidly and almost completely converted in the body to the active metabolite methimazole, which inhibits thyroid peroxidase, thereby blocking the synthesis of thyroid hormones T3 and T4.
Usual adult dose: The initial dose is 20 mg to 60 mg daily, divided into two or three doses. The dose is titrated against thyroid function until the patient is euthyroid. Maintenance dose is usually 5 mg to 15 mg once daily. Therapy is typically continued for at least 6 months and up to 18 months.
Dosage form: Tablets for oral administration (5 mg and 10 mg).
Onset of action: Reduction in thyroid hormone levels begins within 12‑24 hours; clinical improvement in symptoms may take 1‑2 weeks, with full therapeutic effect achieved in 4‑8 weeks.
Duration of action: Once‑daily maintenance dosing is effective; the elimination half‑life of the active metabolite methimazole is approximately 6‑13 hours.
Alcohol consumption should be moderate; heavy alcohol intake may increase the risk of liver problems, a known adverse effect of carbimazole.
Most common side effects: nausea, headache, skin rash, itching, joint pain, and hair thinning.
Would you like to try NeoMercazole without a prescription?

General Information about NeoMercazole

• INN (International Nonproprietary Name): Carbimazole
• Brand names available in the USA: NeoMercazole is not FDA‑approved and is not commercially available in the United States. The active metabolite, methimazole, is available as the brand Tapazole® and in generic forms manufactured by various pharmaceutical companies, including Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., and others.
• ATC code: H03BB01
• Dosage forms and strengths: Tablets: 5 mg and 10 mg. (Also available as 20 mg tablets in some markets.)
• Manufacturers in USA: Not applicable. NeoMercazole is not manufactured or marketed in the United States. Methimazole (Tapazole® and generics) is manufactured by various FDA‑approved manufacturers, including Teva Pharmaceuticals USA, Inc. and Mylan Pharmaceuticals Inc.
• Registration status in USA: Not approved by the U.S. Food and Drug Administration (FDA). Carbimazole has never received marketing approval in the United States. The active metabolite methimazole is FDA‑approved.
• OTC / Rx classification: Prescription only (Rx) in countries where it is approved. In the United States, methimazole (the active metabolite) is a prescription medication.

Mechanism of Action and Pharmacology

Carbimazole is an orally active antithyroid agent belonging to the thionamide class. It is a prodrug that undergoes rapid and virtually complete enzymatic conversion in the bloodstream and gastrointestinal tract to its active metabolite, methimazole (thiamazole). Methimazole exerts its therapeutic effect by irreversibly inhibiting the enzyme thyroid peroxidase (TPO), which is responsible for the iodination of tyrosine residues on thyroglobulin and the coupling of iodotyrosines to form the thyroid hormones triiodothyronine (T3) and thyroxine (T4). By blocking these critical steps in thyroid hormone biosynthesis, carbimazole/methimazole effectively reduces the production and release of thyroid hormones, leading to a gradual decrease in circulating T3 and T4 levels. Unlike propylthiouracil, methimazole does not inhibit the peripheral conversion of T4 to T3. Carbimazole may also possess immunomodulatory properties that contribute to its therapeutic benefit in Graves' disease, an autoimmune condition. Following oral administration, carbimazole is rapidly absorbed, with peak plasma concentrations of methimazole achieved within 1‑2 hours. The elimination half‑life of methimazole is approximately 6‑13 hours, and the drug is excreted primarily in the urine.

Indications

• Treatment of hyperthyroidism, including Graves' disease (diffuse toxic goiter).
• Preparation of hyperthyroid patients for thyroidectomy (surgical removal of the thyroid gland).
• Adjunctive therapy before and during radioactive iodine therapy in selected patients with severe hyperthyroidism.
• Block‑replace regimen: carbimazole is used to block endogenous thyroid hormone production while supplemental levothyroxine is given to maintain euthyroidism.
• Off‑label uses (less common): management of thyrotoxic crisis (thyroid storm), usually in combination with beta‑blockers, corticosteroids, and iodine solutions.

Important Warnings and Precautions

The most serious adverse effect associated with carbimazole is agranulocytosis, a potentially life‑threatening reduction in granulocyte count. Patients must be warned to immediately report any signs of infection, particularly sore throat, fever, mouth ulcers, or flu‑like symptoms, which may indicate bone marrow suppression. If agranulocytosis is suspected, a complete blood count should be obtained urgently, and the drug should be discontinued if confirmed. Hepatotoxicity, including cholestatic jaundice, hepatitis, and acute liver failure, has been reported; liver function should be monitored before and during treatment. Carbimazole can cause hypoprothrombinemia and an increased risk of bleeding, particularly in patients undergoing surgery. Cross‑sensitivity between carbimazole, methimazole, and propylthiouracil has been reported. Caution is required in patients with tracheal compression, esophageal obstruction, or large goiters due to the potential for thyroid gland enlargement during therapy. Hypothyroidism may occur if the dose is excessive; regular monitoring of thyroid function is essential. Carbimazole should be used with caution in patients with renal or hepatic impairment.

At‑risk groups

• Elderly: No specific dose adjustment is required based solely on age, but lower initial doses may be appropriate in elderly patients with mild hyperthyroidism. Elderly patients may be more susceptible to the adverse effects of antithyroid drugs.
• Pregnancy: Carbimazole can be used during pregnancy, but it crosses the placenta and may cause fetal hypothyroidism and goiter. The lowest effective dose should be used. Propylthiouracil is generally preferred during the first trimester due to a potentially lower risk of congenital malformations. Some guidelines recommend switching from carbimazole to propylthiouracil when pregnancy is planned or confirmed. Women of childbearing potential should use reliable contraception during treatment.
• Breastfeeding: Carbimazole is excreted into breast milk in small amounts. If the infant is healthy and monitored, breastfeeding is generally considered acceptable with low‑dose carbimazole. The infant's thyroid function should be monitored periodically. Some guidelines recommend propylthiouracil as the preferred antithyroid drug during breastfeeding.
• Renal impairment: Carbimazole and methimazole are primarily renally excreted. Use with caution in patients with significant renal impairment; dose reduction may be necessary.
• Hepatic impairment: Contraindicated in patients with severe hepatic impairment. Liver function should be monitored before and regularly during treatment. Carbimazole should be discontinued if significant hepatic dysfunction develops.
• Pediatric: Carbimazole can be used in children and adolescents. The initial dose for children is typically 15 mg daily, adjusted based on response. Close monitoring is required due to the risk of adverse effects.
• Bone marrow disorders: Carbimazole is contraindicated in patients with a history of agranulocytosis or significant bone marrow depression caused by carbimazole, methimazole, or propylthiouracil.

Driving and alcohol

Carbimazole is not known to impair the ability to drive or operate machinery. However, some patients may experience dizziness, fatigue, or muscle weakness, which could indirectly affect driving performance. Alcohol consumption should be moderate. Heavy alcohol intake may increase the risk of hepatotoxicity, a known but rare adverse effect of carbimazole. Patients should be advised to limit alcohol consumption and to report any symptoms of liver dysfunction, including jaundice, dark urine, right upper abdominal pain, or unexplained fatigue.

Dosage Instructions

• Adults – initial therapy: The initial dose ranges from 20 mg to 60 mg daily, divided into two or three doses. The dose is determined by the severity of hyperthyroidism and is titrated against thyroid function. Higher doses (up to 80 mg daily) may be required in severe cases.
• Adults – maintenance therapy: Once euthyroidism is achieved (usually after 4‑8 weeks), the dose is gradually reduced to a maintenance level of 5 mg to 15 mg daily, which may be taken as a single daily dose.
• Adults – block‑replace regimen: Carbimazole 20 mg to 60 mg daily is given to block endogenous thyroid hormone production, together with supplemental levothyroxine 50 mcg to 150 mcg daily. This regimen is typically continued for at least 6‑18 months.
• Children (3‑17 years): The usual initial dose is 15 mg daily, divided into two doses. The dose may be adjusted based on response. An alternative weight‑based approach is 0.5 mg/kg daily, divided into two or three doses.
• Elderly: A lower initial dose (e.g., 15 mg daily) may be appropriate, with gradual titration based on thyroid function.
• Renal impairment: Use with caution; dose reduction and/or extended dosing intervals may be required.
• Administration: Tablets should be taken with or after meals to minimize gastrointestinal irritation. They should be swallowed whole with water. Do not crush or chew the tablets.
• Missed dose: If a dose is missed, it should be taken as soon as remembered. If it is almost time for the next dose, the missed dose should be skipped and the regular schedule resumed. Do not double the dose.
• Duration of therapy: Treatment is typically continued for at least 6 months and up to 18 months. Relapse rates after discontinuation range from 30‑70%, depending on the underlying etiology and disease severity.

Side Effects and Contraindications

Common adverse reactions: Nausea, headache, dizziness, skin rash, urticaria, pruritus, arthralgia, myalgia, hair thinning, and mild gastrointestinal upset. These effects are often mild and may resolve with continued treatment or dose reduction.
Serious adverse reactions: Agranulocytosis (incidence 0.3‑0.6%), aplastic anemia, thrombocytopenia, severe hepatotoxicity including cholestatic jaundice and acute hepatitis, hypoprothrombinemia, vasculitis, and lupus‑like syndrome. Agranulocytosis is the most important adverse effect and requires immediate drug discontinuation. Patients must be educated to recognize early signs of infection and to seek urgent medical attention if symptoms develop. Cross‑sensitivity with propylthiouracil has been reported. Angioedema, interstitial pneumonitis, pancreatitis, and myopathy have been reported rarely.
Absolute contraindications: Known hypersensitivity to carbimazole, methimazole, or any excipients; history of agranulocytosis due to carbimazole, methimazole, or propylthiouracil; severe hepatic impairment; and breastfeeding (in some guidelines, propylthiouracil is preferred).

Drug Interactions

• Iodine and iodine‑containing agents (e.g., amiodarone, iodinated contrast media, potassium iodide): Excess iodine may decrease the antithyroid response to carbimazole, requiring dose increases or longer treatment duration.
• Digoxin: Hyperthyroidism increases digoxin clearance; as thyroid function normalizes with carbimazole therapy, digoxin levels may rise. Monitor digoxin serum levels and adjust the dose accordingly.
• Oral anticoagulants (warfarin): Hyperthyroidism potentiates the effect of anticoagulants; as thyroid function normalizes, the anticoagulant effect may decrease. Monitor INR frequently and adjust the anticoagulant dose as necessary.
• Theophylline and aminophylline: Hyperthyroidism increases theophylline clearance; as thyroid function normalizes, theophylline clearance decreases. Monitor theophylline levels and adjust the dose accordingly.
• Prednisolone: Co‑administration of carbimazole with prednisolone may increase prednisolone clearance and decrease its bioavailability.
• Erythromycin: May increase the QT‑prolonging effect of carbimazole/methimazole. Caution is advised, although the risk is primarily associated with intravenous erythromycin.
• Linezolid, sulfamethoxazole, trimethoprim: Concomitant use may increase the risk of myelosuppression, as these agents also have the potential to cause bone marrow depression.
• Alcohol: Heavy alcohol consumption may increase the risk of hepatotoxicity. Moderate intake is generally acceptable, but patients should be advised to limit alcohol.
• Cross‑allergy: There is a risk of cross‑sensitivity between carbimazole, methimazole, and propylthiouracil. Patients allergic to one thionamide may also react to the other.

Practical Advice

• Take NeoMercazole exactly as prescribed, with or after meals to reduce the risk of stomach upset.
• Take the tablets with a full glass of water. Do not crush or chew the tablets.
• Attend all scheduled blood tests, including thyroid function tests (TSH, free T4, free T3) and complete blood count with differential. Regular monitoring is essential for safe and effective therapy.
• Be vigilant for signs of agranulocytosis: fever, sore throat, mouth ulcers, flu‑like symptoms, or any signs of infection. If any of these symptoms occur, stop taking the medication and seek immediate medical attention. A complete blood count should be obtained urgently.
• Watch for signs of liver dysfunction: yellowing of the skin or whites of the eyes (jaundice), dark urine, pale stools, right upper abdominal pain, loss of appetite, nausea, or unexplained fatigue. Report these symptoms to your healthcare provider promptly.
• If you miss a dose, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.
• Do not stop taking NeoMercazole without consulting your healthcare provider. Abrupt discontinuation may result in worsening of hyperthyroidism.
• Inform all healthcare providers (including dentists and surgeons) that you are taking an antithyroid medication. Carbimazole may need to be temporarily discontinued or the dose adjusted before surgical procedures due to an increased risk of bleeding.
• Women of childbearing potential should use reliable contraception during treatment. If pregnancy is planned or suspected, consult a healthcare provider immediately to discuss the risks and benefits of continuing therapy.
• Store at room temperature (below 25°C / 77°F) in a dry place, protected from light and moisture. Keep out of reach of children.
• Do not share this medication with others. NeoMercazole is prescribed for a specific individual based on their thyroid function and medical history.

Alternative Medications

• Methimazole (Tapazole® and generic): The active metabolite of carbimazole; FDA‑approved for the treatment of hyperthyroidism in the United States. Methimazole is the preferred antithyroid drug in the US and is available in 5 mg and 10 mg tablets.
• Propylthiouracil (PTU): Another thionamide antithyroid agent that inhibits thyroid peroxidase and also blocks the peripheral conversion of T4 to T3. Propylthiouracil is preferred during the first trimester of pregnancy and in patients with thyroid storm due to its additional peripheral T4‑to‑T3 conversion‑blocking effect. However, it carries a higher risk of hepatotoxicity compared to methimazole/carbimazole.
• Radioactive iodine (I‑131): A definitive treatment for hyperthyroidism that ablates thyroid tissue. Often preferred for adults with Graves' disease who do not achieve remission with antithyroid drugs. Contraindicated in pregnancy and breastfeeding.
• Thyroidectomy (surgical removal of the thyroid gland): A definitive surgical option for patients with large goiters, suspected malignancy, or those who cannot tolerate antithyroid drugs or radioactive iodine. Requires lifelong thyroid hormone replacement.
• Beta‑blockers (e.g., propranolol, atenolol): Used as adjunctive therapy to control adrenergic symptoms of hyperthyroidism (tachycardia, tremor, anxiety) while awaiting the therapeutic effect of antithyroid drugs.
• Potassium iodide (SSKI) and Lugol's solution: Used in the preparation for thyroidectomy and in the management of thyroid storm to rapidly reduce thyroid hormone release. Not for long‑term use due to the escape phenomenon.

Clinical Efficacy

Carbimazole has been used for decades as first‑line therapy for hyperthyroidism in many countries outside the United States. Clinical studies demonstrate that carbimazole effectively restores euthyroidism in the majority of patients with Graves' disease within 4‑8 weeks of initiating therapy. When used in a block‑replace regimen or dose‑titration regimen, approximately 90‑95% of patients achieve normal or near‑normal thyroid function within 3‑6 months. Long‑term remission rates after 12‑18 months of therapy range from 30‑50%, with higher remission rates observed in patients with mild disease, small goiters, and lower initial thyroid hormone levels. Relapse is most common within the first year after discontinuation. Carbimazole has comparable efficacy and safety to methimazole, and the two agents are considered essentially equivalent in clinical practice. Carbimazole is also effective in the preparation of hyperthyroid patients for thyroidectomy, reducing surgical risk by normalizing thyroid function and decreasing gland vascularity. In pediatric populations, carbimazole effectively controls hyperthyroidism and is used as first‑line therapy, although remission rates in children are lower than in adults.

Important:

NeoMercazole (carbimazole) is a prescription antithyroid medication that must be used under the supervision of a qualified healthcare provider. Regular monitoring of thyroid function and complete blood counts is essential before and during treatment. Agranulocytosis is a rare but potentially life‑threatening adverse effect; patients must be educated to recognize and immediately report any signs of infection, including sore throat, fever, mouth ulcers, or flu‑like symptoms. Carbimazole is not FDA‑approved in the United States; the active metabolite methimazole (Tapazole®) is the preferred antithyroid drug in the US. This medication may cause fetal harm if used during pregnancy; women of childbearing potential should use effective contraception and consult their healthcare provider if pregnancy is planned or suspected. Carbimazole may cause hepatotoxicity; alcohol consumption should be limited, and patients should report any symptoms of liver dysfunction. Do not stop this medication abruptly without consulting your healthcare provider. Inform all healthcare providers, including dentists and surgeons, that you are taking carbimazole. Keep out of reach of children and never share this medication with others. If you experience any serious side effects or signs of allergic reaction, seek immediate medical attention.

How to buy Generic NeoMercazole no prescription U.S. Online Pharmacy